PriceTargets.com logo

NASDAQ:RZLT - Rezolute Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.50
  • Forecasted Upside: 160.83 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$10.16 As of 07/23/2021 01:00 AM ET
▼ -0.34 (-3.24%)

This chart shows the closing price for RZLT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rezolute Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RZLT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RZLT

Analyst Price Target is $26.50
▲ +160.83% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Rezolute in the last 3 months. The average price target is $26.50, with a high forecast of $30.00 and a low forecast of $21.00. The average price target represents a 160.83% upside from the last price of $10.16.

This chart shows the closing price for RZLT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Rezolute.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/26/2021OppenheimerInitiated CoverageOutperform$25.00High
5/25/2021HC WainwrightInitiated CoverageBuy$21.00High
5/12/2021Canaccord GenuityLower Price TargetBuy$33.00 ➝ $30.00High
10/14/2020JMP SecuritiesBoost Price TargetMarket Outperform$28.00 ➝ $30.00Low
10/9/2019JMP SecuritiesInitiated CoverageOutperform$0.55High
9/9/2019Canaccord GenuityInitiated CoverageBuy$0.38High
(Data available from 7/23/2016 forward)
Rezolute logo
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $10.16
Low: $10.00
High: $10.36

50 Day Range

MA: $11.16
Low: $6.24
High: $15.99

52 Week Range

Now: $10.16
Low: $5.86
High: $33.50

Volume

4,776 shs

Average Volume

37,965 shs

Market Capitalization

$84.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Rezolute?

The following Wall Street sell-side analysts have issued reports on Rezolute in the last twelve months: Canaccord Genuity, HC Wainwright, JMP Securities, and Oppenheimer Holdings Inc..
View the latest analyst ratings for RZLT.

What is the current price target for Rezolute?

4 Wall Street analysts have set twelve-month price targets for Rezolute in the last year. Their average twelve-month price target is $26.50, suggesting a possible upside of 160.8%. Canaccord Genuity has the highest price target set, predicting RZLT will reach $30.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $21.00 for Rezolute in the next year.
View the latest price targets for RZLT.

What is the current consensus analyst rating for Rezolute?

Rezolute currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RZLT will outperform the market and that investors should add to their positions of Rezolute.
View the latest ratings for RZLT.

What other companies compete with Rezolute?

Other companies that are similar to Rezolute include Athersys, Neoleukin Therapeutics, DURECT, Oncorus, Theratechnologies, Cue Biopharma, Aerovate Therapeutics, Tonix Pharmaceuticals, Aeglea BioTherapeutics, RedHill Biopharma, UroGen Pharma, Angion Biomedica, Flexion Therapeutics, Puma Biotechnology and MedAvail.

How do I contact Rezolute's investor relations team?

Rezolute's physical mailing address is 201 REDWOOD SHORES PARKWAY SUITE 315, REDWOOD CITY CA, 94065. The company's listed phone number is 650-206-4507 and its investor relations email address is [email protected] The official website for Rezolute is www.rezolutebio.com.